Latest Tax Refunds News

Prescient Therapeutics has secured a key regulatory milestone with the EMA granting Orphan Drug Designation for PTX-100 to treat cutaneous T-cell lymphoma, while expanding its Phase 2a clinical trial across multiple continents.

Nimy Resources has announced a maiden JORC Inferred Resource for high-grade gallium and rare earth elements at its Mons Project in Western Australia, marking a significant step towards becoming a key supplier in critical minerals.

Sparc Technologies has marked a significant milestone with sustained hydrogen production at its pioneering pilot plant and secured key patents, while also achieving its first commercial sale of graphene additives.

Neurotech International has secured a Rare Pediatric Disease Designation from the FDA for its lead drug NTI164 targeting Rett syndrome, alongside publishing promising clinical data and raising $8.7 million to fuel further development.

AdAlta Limited has launched its 'East to West' cellular immunotherapy operations through a strategic collaboration with Shanghai Cell Therapy Group to co-develop BZDS1901, an innovative CAR-T therapy targeting mesothelioma and other solid cancers. The company also strengthened its balance sheet by raising $2.8 million via private placements and repaying key investment agreements.

Spectur Limited reported a 4.5% increase in quarterly revenue to $2.02 million and secured $2.15 million through a share placement to fund its AI-driven Sense-Think-Act platform development.

Agrimin Limited has ceased capital allocation to its Mackay Potash Project following a strategic review, while advancing exploration efforts in the promising West Arunta region.

Zelira Therapeutics has raised nearly US$33 million to fund clinical trials for its HOPE 1 cannabinoid-based medicine targeting autism, while also benefiting from a $1.07 million R&D tax refund.

Li-S Energy has made significant strides in Q4 2025, securing a major government grant, forging key defence partnerships, and commissioning Australia’s first lithium foil production line.

Cleo Diagnostics has broadened its U.S. market opportunity to around 2 million women annually and is on track to complete its pivotal clinical trial early this year, supported by a $5 million capital raise and regulatory progress.

Vitasora Health Limited reported a significant 22% increase in daily clinical billing productivity for the December 2025 quarter, alongside a 17% rise in operating revenue. With new CMS reimbursement policies now in effect, the company anticipates a further 10–20% revenue uplift in 2026.

SenSen Networks has reported record cash receipts for the first half of FY26, driven by strong sales momentum in North America and Australia, alongside innovative product deployments.